The most common type of breast cancer is estrogen receptor-positive (ER+). ER+ tumors can be successfully treated with hormone therapy, but many tumors acquire endocrine resistance which limits treatment options. Sandra D. Scherer, Ph.D. describes the development of an immune-humanized PDX model of estrogen-independent endocrine-resistant ER+ MBC.

свернуть